Gene–environment interactions in sporadic Parkinson's disease

Much has been learned in recent years about the genetics of familial Parkinson's disease. However, far less is known about those malfunctioning genes which contribute to the emergence and/or progression of the vast majority of cases, the ‘sporadic Parkinson’s disease', which is the focus of our current review. Drastic differences in the reported prevalence of Parkinson's disease in different continents and countries suggest ethnic and/or environmental‐associated multigenic contributions to this disease. Numerous association studies showing variable involvement of multiple tested genes in these distinct locations support this notion. Also, variable increases in the risk of Parkinson's disease due to exposure to agricultural insecticides indicate complex gene–environment interactions, especially when genes involved in protection from oxidative stress are explored. Further consideration of the brain regions damaged in Parkinson's disease points at the age‐vulnerable cholinergic‐dopaminergic balance as being involved in the emergence of sporadic Parkinson's disease in general and in the exposure‐induced risks in particular. More specifically, the chromosome 7 ACHE/PON1 locus emerges as a key region controlling this sensitive balance, and animal model experiments are compatible with this concept. Future progress in the understanding of the genetics of sporadic Parkinson's disease depends on globally coordinated, multileveled studies of gene–environment interactions.

[1]  S. Nanko,et al.  No association between Parkinson's disease and monoamine oxidase A and B gene polymorphisms , 1996, Neuroscience Letters.

[2]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[3]  P. Rotwein,et al.  Human tyrosine hydroxylase and insulin genes are contiguous on chromosome 11. , 1988, Nucleic acids research.

[4]  M. Polymeropoulos,et al.  Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients , 2000, Neuroreport.

[5]  W. Rocca Prevalence of Parkinson's disease in China , 2005, The Lancet Neurology.

[6]  Yi-ping Fu,et al.  Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson's disease. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[7]  A. Quattrone,et al.  The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[8]  M. Delong,et al.  Functional neuroanatomy of the basal ganglia in Parkinson's disease. , 2003, Advances in neurology.

[9]  Y Ben-Shlomo,et al.  Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London , 2000, BMJ : British Medical Journal.

[10]  Barry Halliwell,et al.  Failure of the ubiquitin–proteasome system in Parkinson's disease , 2001, Nature Reviews Neuroscience.

[11]  D. Sibley,et al.  Functional Analysis of the Human D2 Dopamine Receptor Missense Variants* , 1996, The Journal of Biological Chemistry.

[12]  A. Whitehead,et al.  Frequency of the apolipoprotein E epsilon 4 allele in a case-control study of early onset Parkinson's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[13]  E. Schwartz,et al.  Paraoxonase 1 Met–Leu 54 polymorphism is associated with Parkinson’s disease , 2001, Journal of the Neurological Sciences.

[14]  L. Bertilsson,et al.  LOW FREQUENCY OF SLOW DEBRISOQUINE HYDROXYLATION IN A NATIVE CHINESE POPULATION , 1987, The Lancet.

[15]  U. Muthane,et al.  Experiences of Parkinson's disease in India , 2002, Lancet Neurology.

[16]  A. Hofman,et al.  CYP2D6 polymorphism in Parkinson's disease: The Rotterdam study , 2001, Movement disorders : official journal of the Movement Disorder Society.

[17]  I. Craig,et al.  Dinucleotide repeat polymorphism at the MAOA locus. , 1991, Nucleic acids research.

[18]  Z. Liu,et al.  No association between paraoxonase 1 (PON1) gene polymorphisms and susceptibility to Parkinson's disease in a Chinese population , 2000, Movement disorders : official journal of the Movement Disorder Society.

[19]  H. Cohen,et al.  The anxiolytic effect of chronic inositol depends on the baseline level of anxiety , 2000, Journal of Neural Transmission.

[20]  M. Oda,et al.  Genetic studies in Parkinson's disease with an α-synuclein/NACP gene polymorphism in Japan , 2001, Neuroscience Letters.

[21]  D. L. Le Couteur,et al.  Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population , 2000, Journal of Neural Transmission.

[22]  Yifu Deng,et al.  Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease , 2004, Annals of neurology.

[23]  E K Perry,et al.  D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. , 1997, Pharmacogenetics.

[24]  C. Négre [Treatment of Parkinson's disease]. , 1986, Soins; la revue de reference infirmiere.

[25]  S. Ho,et al.  G/A1947 polymorphism in catechol‐O‐methyltransferase (COMT) gene in Parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[26]  C. Morris,et al.  Parkinson's disease is not associated with the combined α‐synuclein/apolipoprotein E susceptibility genotype , 2001, Annals of neurology.

[27]  M. Farrer,et al.  Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson’s disease , 1999, Neurology.

[28]  G. Opala,et al.  Catechol-O-Methyltransferase and Monoamine Oxidase B Genes and Susceptibility to Sporadic Parkinson’s Disease in a Polish Population , 2005, European Neurology.

[29]  H. Checkoway,et al.  A pilot study of occupational and environmental risk factors for Parkinson's disease. , 1991, Neurotoxicology.

[30]  Christophe Tzourio,et al.  CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease , 2004, Annals of neurology.

[31]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[32]  C. Goetz,et al.  Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease , 1996, Annals of neurology.

[33]  W. T. Hung,et al.  Genetic and environmental risk factors for Parkinson’s disease in a Chinese population , 1998, Journal of neurology, neurosurgery, and psychiatry.

[34]  Dayu Lin,et al.  Genetic study of apolipoprotein E gene, alpha-1 antichymotrypsin gene in sporadic Parkinson disease. , 2002, American journal of medical genetics.

[35]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[36]  D. Schaid,et al.  Case‐control study of debrisoquine 4‐hydroxylase, n‐acetyltransferase 2, and apolipoprotein e gene polymorphisms in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[37]  A. Quattrone,et al.  NACP-REP1 polymorphism is not involved in Parkinson's disease: a case-control study in a population sample from southern Italy , 2003, Neuroscience Letters.

[38]  M. Oda,et al.  Genetic studies in Parkinson's disease with an alpha-synuclein/NACP gene polymorphism in Japan. , 2001, Neuroscience letters.

[39]  J. Jankovic,et al.  Variability and validity of polymorphism association studies in Parkinson’s disease , 2000, Neurology.

[40]  Josemir W Sander,et al.  The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. , 2000, Brain : a journal of neurology.

[41]  V. Hachinski,et al.  Environmental Exposures in Elderly Canadians With Parkinson’s Disease , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[42]  A. Kuwano,et al.  Association analysis of a polymorphism of the monoamine oxidase B gene with Parkinson's disease in a Japanese population. , 1995, American journal of medical genetics.

[43]  D. Buchanan,et al.  Variations in the monoamine oxidase B lpar;MAOB) gene are associated with Parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.

[44]  B. Müller-Myhsok,et al.  The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[45]  S. Nanko,et al.  Association study of structural mutations of the tyrosine hydroxylase gene with schizophrenia and Parkinson's disease. , 1998, American journal of medical genetics.

[46]  Hagai Bergman,et al.  Stepping out of the box: information processing in the neural networks of the basal ganglia , 2001, Current Opinion in Neurobiology.

[47]  R. Krüger,et al.  Increased susceptibility to sporadic Parkinson's disease by a certain combined α‐synuclein/apolipoprotein E genotype , 1999, Annals of neurology.

[48]  G. Savettieri,et al.  Lack of association between ubiquitin carboxy-terminal hydrolase L1 gene polymorphism and PD , 2001, Neurology.

[49]  R. Zivadinov,et al.  Familial and environmental risk factors in Parkinson's disease: a case–control study in north‐east Italy , 2002, Acta neurologica Scandinavica.

[50]  S. Sawcer,et al.  The genetic basis of Parkinson's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[51]  A. Chiò,et al.  Prevalence of Parkinson's disease in northwestern italy: Comparison of tracer methodology and clinical ascertainment of cases , 1998, Movement disorders : official journal of the Movement Disorder Society.

[52]  C. Markham,et al.  Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease , 1994, Movement disorders : official journal of the Movement Disorder Society.

[53]  C. Brayne,et al.  The Epidemiology of Parkinson’s Disease in an Australian Population , 1998, Neuroepidemiology.

[54]  M. Anvret,et al.  Further evidence for an association of the Paraoxonase 1 (PON1) Met‐54 allele with Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[55]  M. Druet‐Cabanac,et al.  Parkinson’s Disease and Environmental Factors , 2000, Neuroepidemiology.

[56]  P. Jenner Parkinson's disease, pesticides and mitochondrial dysfunction , 2001, Trends in Neurosciences.

[57]  M. Druet‐Cabanac,et al.  Parkinson's disease and environmental factors. Matched case-control study in the Limousin region, France. , 2000, Neuroepidemiology.

[58]  E. Love,et al.  Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.

[59]  G. Jarvik,et al.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. , 2001, American journal of human genetics.

[60]  E. Shahar,et al.  Extra-pyramidal parkinsonism complicating organophosphate insecticide poisoning. , 2001, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[61]  O. Axelson,et al.  Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. , 1996, Journal of clinical epidemiology.

[62]  T. Dawson,et al.  Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease , 2000, Neurobiology of Disease.

[63]  V. Lee,et al.  A new link between pesticides and Parkinson's disease , 2000, Nature Neuroscience.

[64]  P. Taba,et al.  Prevalence of Parkinson's disease in Estonia , 2002, Acta neurologica Scandinavica.

[65]  R. Wu,et al.  Pesticides exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson's disease. , 2005, Acta neurologica Taiwanica.

[66]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[67]  A. Hofman,et al.  N-acetyltransferase-2 polymorphism in Parkinson’s disease: the Rotterdam study , 1999, Journal of neurology, neurosurgery, and psychiatry.

[68]  B. Dick,et al.  [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population]. , 1982, Schweizerische medizinische Wochenschrift.

[69]  F. Jiménez-Jiménez,et al.  Risk‐factors for Parkinson's disease: case‐control study in the province of Cáceres, Spain , 1994, Acta neurologica Scandinavica.

[70]  M. Felgueiras,et al.  The prevalence of Parkinson's disease in Portugal , 1994, European Journal of Epidemiology.

[71]  I. Kondo,et al.  Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease , 1998, Brain Research.

[72]  C. Marsden,et al.  Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase , 1998, Neuroscience.

[73]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[74]  R. Duvoisin Cholinergic-anticholinergic antagonism in parkinsonism. , 1967, Archives of neurology.

[75]  Anthony M. Kang,et al.  Global variation of a 40-bp VNTR in the 3′-untranslated region of the dopamine transporter gene (SLC6A3) , 1999, Biological Psychiatry.

[76]  O. Axelson,et al.  Nutritional and occupational factors influencing the risk of Parkinson's disease: A case‐control study in southeastern Sweden , 1999, Movement disorders : official journal of the Movement Disorder Society.

[77]  M Behari,et al.  Risk factors of Parkinson's disease in Indian patients , 2001, Journal of the Neurological Sciences.

[78]  J. Goldsmith,et al.  A Case-Control Study of Parkinson's Disease in Urban Population of Southern Israel , 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[79]  J. Somberg Genetic polymorphisms. , 2002, American journal of therapeutics.

[80]  D. Collier,et al.  High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease , 1997, Neuroscience Letters.

[81]  D. Collier,et al.  No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase. , 1996, Biochemical and biophysical research communications.

[82]  P. Amouyel,et al.  S18Y polymorphism in the UCH‐L1 gene and Parkinson's disease: Evidence for an age‐dependent relationship , 2003, Movement disorders : official journal of the Movement Disorder Society.

[83]  E. Teng,et al.  A door-to-door survey of Parkinson's disease in a Chinese population in Kinmen. , 1996, Archives of neurology.

[84]  A. Seidler,et al.  Possible environmental, occupational, and other etiologic factors for Parkinson's disease , 1996, Neurology.

[85]  S. Cichon,et al.  Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. , 1994, Human molecular genetics.

[86]  X Li,et al.  Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. , 1992, Genomics.

[87]  A. Saiardi,et al.  Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors , 1995, Nature.

[88]  J. Hubble,et al.  Risk factors for Parkinson's disease , 1993, Neurology.

[89]  D. Grandy,et al.  The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. , 1989, American journal of human genetics.

[90]  V. Uversky,et al.  Pesticides directly accelerate the rate of α‐synuclein fibril formation: a possible factor in Parkinson's disease , 2001, FEBS letters.

[91]  K. Jellinger,et al.  Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.

[92]  H. Chern,et al.  The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese , 2001, Neurology.

[93]  D. L. Le Couteur,et al.  The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis , 1997, Journal of the Neurological Sciences.

[94]  A. Lang,et al.  Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.

[95]  C. C. Johnson,et al.  The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.

[96]  J. Woo,et al.  Lack of allelic association of dopamine D4 receptor gene polymorphisms with Parkinson's disease in a chinese population , 1999, Movement disorders : official journal of the Movement Disorder Society.

[97]  K. Marder,et al.  The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. , 1995, American journal of epidemiology.

[98]  J. Idle,et al.  Allelic association between the DRD2 TaqI A polymorphism and Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[99]  J. Nutt,et al.  Environmental antecedents of young‐onset Parkinson's disease , 1993, Neurology.

[100]  Y Ben-Shlomo,et al.  The epidemiology of Parkinson's disease. , 1997, Bailliere's clinical neurology.

[101]  K. Leenders,et al.  Hydrocarbon exposure and Parkinson’s disease , 2000, Neurology.

[102]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[103]  H. Checkoway,et al.  Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease. , 1998, American journal of medical genetics.

[104]  G. Morgan,et al.  Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. , 2000, Pharmacogenetics.

[105]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[106]  J. Woo,et al.  The dopamine transporter gene and Parkinson's disease in a Chinese population , 1997, Neurology.

[107]  J. Dartigues,et al.  Association between Parkinson’s Disease and Exposure to Pesticides in Southwestern France , 2003, Neuroepidemiology.

[108]  P. Tienari,et al.  Apolipoprotein E (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson's disease in Finland , 2002, Neuroscience Letters.

[109]  J. Andersen,et al.  Glutathione, iron and Parkinson's disease. , 2002, Biochemical pharmacology.

[110]  J. Woo,et al.  Comparison of Environmental and Genetic Factors for Parkinson’s Disease between Chinese and Caucasians , 2004, Neuroepidemiology.

[111]  B. Summers,et al.  Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease , 1992, The Lancet.

[112]  Y. Teo,et al.  Alpha-synuclein haplotypes implicated in risk of Parkinson’s disease , 2004, Neurology.

[113]  Y. M. Shi,et al.  Parkinson's disease in China. Coordinational Group of Neuroepidemiology, PLA. , 1991, Chinese medical journal.

[114]  D. Krikovszky,et al.  Altered Distribution of the Debrisoquine Oxidative Phenotypes in Children with Type 1 Diabetes mellitus , 2004, Hormone Research in Paediatrics.

[115]  H. Checkoway,et al.  Genetic polymorphism of dopamine D2 receptors in Parkinson's disease and interactions with cigarette smoking and MAO-B intron 13 polymorphism , 2000, Journal of neurology, neurosurgery, and psychiatry.

[116]  F. Jiménez-Jiménez,et al.  Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease , 1998, Neurology.

[117]  U. Rinne,et al.  EPIDEMIOLOGY of PARKINSON'S DISEASE IN FINLAND , 1976, Acta neurologica Scandinavica.

[118]  Jeffrey H. Kordower,et al.  The role of α-synuclein in Parkinson's disease: insights from animal models , 2003, Nature Reviews Neuroscience.

[119]  B. Liu,et al.  Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. , 2003, Environmental health perspectives.

[120]  Jeffrey H Kordower,et al.  The role of alpha-synuclein in Parkinson's disease: insights from animal models. , 2003, Nature reviews. Neuroscience.

[121]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[122]  I. Kondo,et al.  Genetic association between cytochrome P450IA1 gene and susceptibility to Parkinson's disease , 2005, Journal of Neural Transmission.

[123]  D. Grandy,et al.  Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. , 1991, Genomics.

[124]  K K Kidd,et al.  A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. , 1993, Human molecular genetics.

[125]  D. Collier,et al.  The –141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson's disease , 2001, Psychiatric genetics.

[126]  A. Singleton,et al.  Paraoxonase 1 (PON1) gene polymorphisms and Parkinson’s disease in a Finnish population , 2004, Neuroscience Letters.

[127]  S. Gruber,et al.  The epidemiology of Parkinson's disease. A case-control study of young-onset and old-onset patients. , 1991 .

[128]  W. Koller,et al.  Environmental risk factors in siblings with Parkinson's disease. , 1991, Archives of neurology.

[129]  J. Idle,et al.  Mutant debrisoquine hydroxylation genes in Parkinson's disease , 1992, The Lancet.

[130]  D. Maraganore,et al.  Tyrosine hydroxylase polymorphism in familial and sporadic Parkinson's disease , 1994, Movement disorders : official journal of the Movement Disorder Society.

[131]  Toshiaki Tanaka,et al.  Growth Hormone Treatment in Short Japanese Children Born Small for Gestational Age , 2004, Hormone Research in Paediatrics.

[132]  M. Roy,et al.  Facteurs environnementaux dans l'étiologie de la maladie de Parkinson , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[133]  C. Hertzman,et al.  A case‐control study of Parkinson's disease in a horticultural region of British Columbia , 1994, Movement disorders : official journal of the Movement Disorder Society.

[134]  S. Khuder,et al.  Environmental risk factors and Parkinson's disease: a metaanalysis. , 2001, Environmental research.

[135]  W. T. Hung,et al.  Lack of association between CYP1A1 polymorphism and Parkinson's disease in a Chinese population , 2002, Journal of Neural Transmission.

[136]  J. Kurth,et al.  Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. , 1993, American journal of medical genetics.

[137]  Hagai Bergman,et al.  Identifying subtle interrelated changes in functional gene categories using continuous measures of gene expression , 2005, Bioinform..

[138]  C. Tanner,et al.  CYP2D6 allelic frequencies in young-onset Parkinson's disease , 1996, Neurology.

[139]  E. Lee,et al.  Evidence for the polymorphic oxidation of debrisoquine in the Thai population. , 1990, British journal of clinical pharmacology.

[140]  F. Jiménez-Jiménez,et al.  Exposure to well water and pesticides in Parkinson's disease: A case‐control study in the madrid area , 1992, Movement disorders : official journal of the Movement Disorder Society.

[141]  J. De Pedro-Cuesta,et al.  Prevalence of Parkinson's disease in lower Aragon, Spain , 1999, Movement disorders : official journal of the Movement Disorder Society.

[142]  D. L. Le Couteur,et al.  Association of a polymorphism in the dopamine‐transporter gene with parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[143]  A. Barbeau The pathogenesis of Parkinson's disease: a new hypothesis. , 1962, Canadian Medical Association journal.

[144]  A. L. Werneck,et al.  Genetics, drugs and environmental factors in Parkinson's disease. A case-control study. , 1999, Arquivos de neuro-psiquiatria.

[145]  D. Ramsden,et al.  An allelic association study of monoamine oxidase B in parkinson's disease , 1995, Annals of neurology.

[146]  P. Silburn,et al.  The monoamine oxidase B gene GT repeat polymorphism and Parkinson’s disease in a Chinese population , 2000, Journal of Neurology.

[147]  S. Ho,et al.  Epidemiologic study of Parkinson's disease in Hong Kong , 1989, Neurology.

[148]  K. Honda,et al.  Detection and analysis of four polymorphic markers at the human monoamine oxidase (MAO) gene in Japanese controls and patients with Parkinson's disease. , 1998, Biochemical and biophysical research communications.

[149]  I. Milanov,et al.  Prevalence of Parkinson’s Disease in Bulgaria , 2001, Neuroepidemiology.

[150]  O. Livnah,et al.  Inherited and acquired interactions between ACHE and PON1 polymorphisms modulate plasma acetylcholinesterase and paraoxonase activities , 2005, Journal of neurochemistry.

[151]  C. Tanner,et al.  Environmental Factors in the Etiology of Parkinson's Disease , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[152]  M. P. Turpin,et al.  Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. , 1996, Biochemical and biophysical research communications.

[153]  T. Riise,et al.  The epidemiology of Parkinson's disease in the county of Rogaland, Norway , 1995, Movement disorders : official journal of the Movement Disorder Society.

[154]  M. Rundle,et al.  Association of variations in monoamine oxidases A and B with Parkinson's disease subgroups. , 2004, Genomics.

[155]  K. Kawajiri,et al.  Genetic Polymorphisms in the 5 '-Flanking Region Change Transcriptional Regulation of the Human Cytochrome P 45011 E 1 Gene ' , 2008 .

[156]  Ichiro Kanazawa,et al.  Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms , 2002, Annals of neurology.

[157]  M. Hernán,et al.  MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD , 2002, Neurology.

[158]  S. Kikuchi,et al.  Prevalence of Parkinson's disease in Hokkaido, the northernmost island of Japan. , 1996, Internal medicine.

[159]  D. Maraganore,et al.  Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease , 2005, Neuroscience Letters.

[160]  T. Sherer,et al.  Environment, Mitochondria, and Parkinson's Disease , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[161]  N. Hattori,et al.  Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan , 2005, Journal of Neural Transmission.

[162]  G. Jarvik,et al.  Paraoxonase 1 promoter and coding region polymorphisms in Parkinson’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[163]  R. Fukuda,et al.  No allelic association between Parkinson's disease and dopamine D2, D3, and D4 receptor gene polymorphisms. , 1994, American journal of medical genetics.

[164]  R. Mahley,et al.  Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. , 1999, Current opinion in lipidology.

[165]  C D Marsden,et al.  Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease , 1997, Neurology.

[166]  P. Fender,et al.  [Prevalence of thirty long term disorders for French health insurance members in 1994]. , 1997, Revue d'epidemiologie et de sante publique.

[167]  R. Barker,et al.  The heterogeneity of idiopathic Parkinson's disease , 2002, Journal of Neurology.

[168]  Marguerite Wieler,et al.  Treatment of Parkinson's Disease , 2003, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[169]  L. Svenson,et al.  Geographic Variations in the Prevalence Rates of Parkinson’s Disease in Alberta , 1993, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[170]  J R Goldsmith,et al.  A Case-Referent Study of Extrapyramidal Signs (Preparkinsonism) in Rural Communities of Israel , 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[171]  C. Tanner,et al.  Environmental factors and Parkinson's disease , 1989, Neurology.

[172]  A. Blackburn,et al.  Parkinson's disease, pesticides, and glutathione transferase polymorphisms , 1998, The Lancet.

[173]  J. Trojanowski,et al.  Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease , 1995, Journal of neural transmission. Parkinson's disease and dementia section.

[174]  J. Jankovic,et al.  Polymorphism of NACP-Rep1 in Parkinson’s disease: An etiologic link with essential tremor? , 2000, Neurology.

[175]  J. A. Dani,et al.  Muscarinic and Nicotinic Cholinergic Mechanisms in the Mesostriatal Dopamine Systems , 2003, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[176]  A. Persad,et al.  Parkinson’s Disease and CYP2D6 Polymorphism in Asian Populations: A Meta-Analysis , 2003, Neuroepidemiology.

[177]  M. Farrer,et al.  Case‐Control study of dopamine transporter‐1, monoamine oxidase‐B, and catechol‐O‐methyl transferase polymorphisms in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[178]  A. Smargiassi,et al.  A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. , 1998, Neurotoxicology.

[179]  D. S. Rath,et al.  Tetranucleotide repeat polymorphism at the human tyrosine hydroxylase gene (TH). , 1991, Nucleic acids research.

[180]  M. Brin,et al.  Anticholinergic therapies in the treatment of Parkinson's disease , 2002 .

[181]  Yi Zhao,et al.  Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[182]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[183]  J. Kurth,et al.  Association of a monoamine oxidase B allele with Parkinson's disease , 1993, Annals of neurology.

[184]  W. Rocca,et al.  Prevalence of Parkinson's disease in junín, Buenos Aires province, argentina , 1997, Movement disorders : official journal of the Movement Disorder Society.

[185]  B. Schoenberg,et al.  A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. , 1985, Archives of neurology.

[186]  S. Mandel,et al.  Green tea polyphenol (–)‐epigallocatechin‐3‐gallate prevents N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurodegeneration , 2001, Journal of neurochemistry.

[187]  J. Gorell,et al.  Environmental Risk Factors for Parkinson's Disease , 2003 .

[188]  L. Golbe,et al.  Follow‐up study of early‐life protective and risk factors in Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.

[189]  W. T. Hung,et al.  Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese , 2003, Neurology.

[190]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[191]  P. Silburn,et al.  The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease , 2000, Neuroscience Letters.

[192]  D. Kömpf,et al.  Epidemiology and out-patient care in Parkinson's disease--results from a pilot-study in northern Germany (Schleswig-Holstein). , 1991, Journal of neural transmission. Supplementum.

[193]  M. Nöthen,et al.  Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers , 1999, Molecular Psychiatry.

[194]  D. Hernandez,et al.  alpha-Synuclein gene haplotypes are associated with Parkinson's disease. , 2001, Human molecular genetics.

[195]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[196]  C. Hertzman,et al.  Parkinson's disease: a case-control study of occupational and environmental risk factors. , 1990, American journal of industrial medicine.

[197]  G. Defazio,et al.  Epidemiology of primary blepharospasm , 2002, Movement disorders : official journal of the Movement Disorder Society.

[198]  Matthew J. Farrer,et al.  α-synuclein gene haplotypes are associated with Parkinson’s disease , 2001 .

[199]  R. Ebstein,et al.  Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide‐induced Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[200]  H. Helenius,et al.  Environmental risk factors in Parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.

[201]  F. Aboitiz,et al.  Does bigger mean better? Evolutionary determinants of brain size and structure. , 1996, Brain, behavior and evolution.

[202]  J. Satoh,et al.  A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population , 2001, Journal of the Neurological Sciences.

[203]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[204]  G. Campanella,et al.  [Environmental factors in the etiology of Parkinson's disease]. , 1990, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques.